Understanding how a toxin from a harmful bacteria interacts with human cells
Determine host surface interactions of MARTX toxin of foodborne Vibrio vulnificus
This study is looking at how a harmful toxin from a bacteria called Vibrio vulnificus interacts with our cells, which could help us find new ways to treat infections caused by this bacteria, especially since some strains are becoming harder to treat with antibiotics.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10892926 on NIH RePORTER |
What this research studies
This research investigates the interactions between the MARTX toxin produced by the bacteria Vibrio vulnificus and human host cells. By using advanced techniques like CRISPR-Cas9 screening, the study aims to identify specific host cell receptors that the toxin binds to, which is crucial for understanding how the bacteria causes severe infections. The findings could lead to the development of new therapeutic strategies, such as antibodies that can block the toxin's effects, ultimately improving patient outcomes. This research is particularly relevant as antibiotic-resistant strains of this bacteria are on the rise.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of infections from Vibrio vulnificus, particularly those with open wounds or those consuming raw seafood.
Not a fit: Patients who are not at risk of Vibrio vulnificus infections, such as those without open wounds or those who do not consume raw seafood, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent severe infections caused by Vibrio vulnificus.
How similar studies have performed: Other research has shown success in understanding bacterial toxins and their interactions with host cells, making this approach promising.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Chen, Jiexi — Northwestern University at Chicago
- Study coordinator: Chen, Jiexi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.